DUBLIN--(BUSINESS WIRE)--The "Western Blotting: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for Western blotting was valued at $1.4 billion in 2022 ...

Bio-Rad Laboratories, Inc. (BIO) has experienced a rise in revenue growth in recent years thanks to strong sales of its Western Blotting, Digital PCR, and Process Media life science products. Several ...

Bio-Rad Laboratories Inc (NYSE:BIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the ongoing ...

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Bio-Rad Third Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] And please be advised ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of the ChemiDoc MP Digital Imaging System. The imager combines the industry’s best performance with ease of use and is ideal ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies.

Bio-Rad Laboratories, Inc. BIO is set to release second-quarter 2023 results on Aug 3 after the closing bell. The company posted adjusted earnings per share (EPS) of $3.34 in the last reported quarter ...